ESMO 2025

Reassuring data on pregnancy for young EBC patients

Toward a new standard - T-DXd in early breast cancer

Rethinking dosing in TNBC

Refining the standard treatments for early breast…

T-DXd in high-risk patients in the postneoadjuvant…

Exciting news for young patients who want to get…

POSITIVE trial - update

CDK4/6 inhibitors – confirmed effect

Individual consultation remains important

T-DXd neoadjuvant improves pCR

Financial toxicity

First time OS - confirming clinical practice

OS-benefit with abemaciclib

Great update for young women

A first step into a great story

The first neoadjuvant therapy decreases chemotherapy in…

Adjuvant data with CDK4/6 inhibitors in HR+ breast…

New insights into PROTAC SERD vepdegestrant

Optimal timepoint of G-CSF administration after…

Optimizing G-CSF administration helps reducing side…

monarchE OS

Ki67 after preoperative chemotherapy - a new strong…

Durvalumab improves OS in TNBC

Prima valutazione della OS: conferma della pratica…

Un primer paso hacia una gran historia

Studio POSITIVE - aggiornamento

La primera terapia neoadyuvante reduce la quimioterapia…

monarchE OS

Momento óptimo para la administración de G-CSF después…

Future perspectives for firstline therapy

Future perspectives on TNBC therapy

Practice changing data for firstline TNBC

Reforming destiny

Meeting the unmet need in advanced TNBC not eligible…

Early positioning of third-generation ADCs in treatment

Stronger together

TROP2 ADC, the second

Another good option for patients with mTNBC

Which ADC in 1L for metastatic TNBC

ADC, the first

TROP2 number 3

Breakthroughs for high-risk patients

Combination matters

Gedatolisib in patients with PI3K wild type HR+ mBC

Should this drug be available outside of China?

ADCs are coming for first line TNBC

Survival data from SONIA

Changing the paradigm of treatment in 1L of TNBC

Gedatolisib in pazienti con mBC HR+ PI3K wild type

Cambiando el paradigma del tratamiento en la primera…

Gli ADC si fanno strada nella prima linea del TNBC

Otra buena opción para pacientes con mTNBC

Gedatolisib chez les patients atteints d'un cancer du…

Più forti insieme

La combinazione conta

Nowa szansa dla chorych na zaawansowanego, potrójnie…

Immunotherapy and biomarkers in resectable NSCLC:…

Evolving immunotherapy approaches in locally advanced…

Neoadjuvant chemo/immuno - the bridge to make…

New chances for locally advanced NSCLC

ALEX: Long-term OS benefit with Alectinib in ALK+ NSCLC

Therapy sequencing after EGFR-TKI progression: insights…

New targeted therapies in HER2-mutated NSCLC

NorthStar: Osimertinib ± local therapy in EGFR-mutant…

The added value of radiotherapy in EGFR mutated NSCLC

New chances for locally advanced NSCLC

EGFR exon 20 - What does the future hold?

Two is better than one

New prospect for squamous tumors

Anti-TROP-2 ADCS - new data in EGFRm NSCLC

NorthStar - new navigation principle

Update for pts with BRAF mutation

New treatment options for HER2-mutation positive NSCLC

New kid on the block for EGFRm

Save and effective - Ivonescimab in HARMONi-6

New options after EGFR-TKI failure

HER2 altered - small population, many options

Alectinib remains a potential SOC

Two frontline HER2-options - is this the future?

sac-TMT a new SOC

Local ablative therapy in EGFR-mutated NSCLC

Is this the end for pembrolizumab?

Sac-TMT now also available for NSCLC

ALK - longterm

Sac-TMT - a potential new option for EGFRm NSCLC…

Local therapy in addition to osimertinib 1st line in…

The return of antiangiogenic strategy in squamous NSCLC

Ivonescimab in NSCLC - a new SOC?

Is chemo-IO an option if you want a rapid response in…

Treat your BRAF-patients in 1L

Le retour de la stratégie antiangiogénique dans le…

De toegevoegde waarde van radiotherapie bij…

New kid on the block for EGFRm

ADCS anti-TROP-2 - nouvelles données sur le EGFRm NSCLC

Nuevas perspectivas para los tumores escamosos

Due è meglio di uno

Sac - TMT - une nouvelle option potentielle pour le…

Prognostic role of exosomes in stage IIIA(N2) NSCLC…

Molecular factors and ctDNA dynamics linked to outcomes…

Tarlatamab combination in 1st line SCLC

Bending the gravity of SCLC

DLL3 targeting drugs moving to frontline therapy

Dramatic improvement of PFS in 1L treatment

Will tarlatamab improve 1st line treatment for…

Amélioration spectaculaire de la survie sans…

Doblando la gravedad del SCLC

The hippo-pathway in Mesothelioma

Adding to the adjuvant RCC story - how do we move…

Another part of the puzzle

Further intensification of therapy with potential…

Input for the second line in ccRCC

Relevance of CPI neoadjuvant and adjuvant

Therapy-relevant aspects for first-line treatment of…

More evidence in second-line treatment for metastatic…

Kidney cancer advances from ESMO

LenCabo - early activity, but we need more data

The dawn of molecular imaging in renal cell carcinoma

MIBC: Is ctDNA monitoring ready for daily practice?

NMIBC: Making the right choice for high risk patients!

UTUC: Impressive PFS und OS Benefit with Disitamab…

The ADC story continues

Setting the bar even higher in MIBC

A highly selective FGFR3 inhibitor for first-line…

New benchmark for MIBC and platinum-unsuitable patients

Neoadjuvant HER2-targeted therapy for kidney-sparing…

Neoadjuvant combination of local and systemic therapy…

Therapy intensification in patients ineligible for…

Perioperative and adjuvant standards for MIBC

De-escalation promotes a better QoL while maintaining…

Too early for primetime

Better QoL for patients with metastatic bladder cancer

Bladder cancer highlights from ESMO 2025

When precision matters, the case of ctDNA in MIBC

A newcomer in advanced urothelial cancer

Negative, but important data to discuss

ADC Enfortumab vedotin + Pembrolizumab in MIBC

Is ICI to BCG suitable for NMIBC?

Dose modifications, new combinations, new substances in…

New options for neoadjuvant therapy in MIBC

A well-tolerated and effective new neoadjuvant concept…

Κύρια σημεία για τον καρκίνο της ουροδόχου κύστης από…

Elevando aún más el estándar en MIBC

Cuando la precisión importa: el caso de ctDNA en MIBC

Données négatives, mais importantes à discuter

Is this the new standard of care?

Impressive OS-data from EMBARK

Example for biomarker guided precision medicine in…

New docetaxel regimen in combination with darolutamide…

Final OS results for EMBARK

Practice-changing data for mHSPC

Changed chemo-regimen leads to less toxicity in mHSPC

The role of lutetium in mHSPC – is its use clinically…

Triplet regimen with reduced chemotherapy – fewer side…

Docetaxel vs. Lutetium in chemosensitive mCRPC

PSMAddition - Is it time for more?

Imponerande OS-data från EMBARK

Ändrad kemoterapiregim leder till mindre toxicitet vid…

Thymic tumors - heads up